Literature DB >> 16873896

Down-regulation of beta1,4-galactosyltransferase V is a critical part of etoposide-induced apoptotic process and could be mediated by decreasing Sp1 levels in human glioma cells.

Jianhai Jiang1, Jialin Shen, Tao Wu, Yuanyan Wei, Xiaoning Chen, Hongliang Zong, Si Zhang, Maoyun Sun, Jianhui Xie, Xiangfei Kong, Yanzhong Yang, Aiguo Shen, Hanzhou Wang, Jianxin Gu.   

Abstract

beta1,4-Galactosyltransferase V (beta1,4GalT V; EC 2.4.1.38) is considered to be very important in glioma for expressing transformation-related highly branched N-glycans. Recently, we have characterized beta1,4GalT V as a positive growth regulator in several glioma cell lines. However, the role of beta1,4GalT V in glioma therapy has not been clearly reported. In this study, interfering with the expression of beta1,4GalT V by its antisense cDNA in SHG44 human glioma cells markedly promoted apoptosis induced by etoposide and the activation of caspases as well as processing of Bid and expression of Bax and Bak. Conversely, the ectopic expression of beta1,4GalT V attenuated the apoptotic effect of etoposide on SHG44 cells. In addition, both the beta1,4GalT V transcription and the binding of total or membrane glycoprotein with Ricinus communis agglutinin-I (RCA-I) were partially reduced in etoposide-treated SHG44 cells, correlated well with a decreased level of Sp1 that has been identified as an activator of beta1,4GalT V transcription. Collectively, our results suggest that the down-regulation of beta1,4GalT V expression plays an important role in etoposide-induced apoptosis and could be mediated by a decreasing level of Sp1 in SHG44 cells, indicating that inhibitors of beta1,4GalT V may enhance the therapeutic efficiency of etoposide for malignant glioma.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16873896     DOI: 10.1093/glycob/cwl027

Source DB:  PubMed          Journal:  Glycobiology        ISSN: 0959-6658            Impact factor:   4.313


  6 in total

Review 1.  Estrogen-Driven Changes in Immunoglobulin G Fc Glycosylation.

Authors:  Kaitlyn A Lagattuta; Peter A Nigrovic
Journal:  Exp Suppl       Date:  2021

2.  Diazoxide-mediated growth inhibition in human lung cancer cells via downregulation of beta-catenin-mediated cyclin D1 transcription.

Authors:  Jianyong Ding; Di Ge; Weigang Guo; Chunlai Lu
Journal:  Lung       Date:  2008-12-04       Impact factor: 2.584

Review 3.  Convergence: Lactosylceramide-Centric Signaling Pathways Induce Inflammation, Oxidative Stress, and Other Phenotypic Outcomes.

Authors:  Subroto Chatterjee; Amrita Balram; Wendy Li
Journal:  Int J Mol Sci       Date:  2021-02-12       Impact factor: 5.923

4.  Use of a glycolipid inhibitor to ameliorate renal cancer in a mouse model.

Authors:  Subroto Chatterjee; Nezar Alsaeedi; Jennifer Hou; Veera Venkata Ratnam Bandaru; Lan Wu; Marc K Halushka; Roberto Pili; Georges Ndikuyeze; Norman J Haughey
Journal:  PLoS One       Date:  2013-05-09       Impact factor: 3.240

5.  Increased B4GALT1 expression associates with adverse outcome in patients with non-metastatic clear cell renal cell carcinoma.

Authors:  Huyang Xie; Yu Zhu; Huimin An; Hongkai Wang; Yao Zhu; Hangcheng Fu; Zewei Wang; Qiang Fu; Jiejie Xu; Dingwei Ye
Journal:  Oncotarget       Date:  2016-05-31

Review 6.  Arsenic trioxide as a novel anti-glioma drug: a review.

Authors:  Yi Fang; Zhen Zhang
Journal:  Cell Mol Biol Lett       Date:  2020-09-24       Impact factor: 5.787

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.